


Cimicide E

Cat. No.:	HY-N10018
CAS No.:	154822-57-8
Molecular Formula:	C ₃₅ H ₅₄ O ₈
Molecular Weight:	602.8
Target:	Caspase
Pathway:	Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Cimicide E (25-Anhydrocimigenol xyloside) is a triterpene xyloside, Cimicide E possesses apoptotic action on gastric cancer cells, with an IC ₅₀ value of 14.58 μM. Cimicide E induces cell cycle arrest at G2/M phase, and mediates apoptosis through the induction of the caspase cascade for both the extrinsic and intrinsic pathways ^{[1][2]} .																
IC₅₀ & Target	Caspase 3																
In Vitro	<p>Cimicide E (30-90 μM; 24 h) arrest cell cycle and induces apoptosis in ASG cells^[1].</p> <p>Cimicide E (30-90 μM; 12-48 h) has a strong cytotoxicity on AGS cells and shows anti-proliferative activity^[1].</p> <p>Cimicide E (15-60 μM; 6-24 h) induces DNA fragment, (30-60; 1-6 h) activates expression of FasL at 3 h and Fas from 1 h in ASG cells^[1].</p> <p>Cimicide E (30-90 μM; 3-24 h) mediates caspase cascade, by increasing Bax/Bcl-2 ratio and decreasing mutant type (mt) p53 and procaspase 3^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Cimicide E. AGS cells</td> </tr> <tr> <td>Concentration:</td> <td>30 μM, 60 μM, and 90 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>3 h, 6 h, 12 h, and 24 h</td> </tr> <tr> <td>Result:</td> <td>Increased the ratio of Bax/Bcl-2 expression from 60 μM. Decreased mutant type (mt) p53 level from 12 h at 30 μM. Suppressed the protein level of procaspase 3 in a dose-dependent manner from 30 μM.</td> </tr> </table> <p>Cell Proliferation Assay^[1]</p> <table border="1"> <tr> <td>Cell Line:</td> <td>Cimicide E. AGS cells</td> </tr> <tr> <td>Concentration:</td> <td>30 μM, 60 μM, and 90 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>12 h, 24 h, and 48 h</td> </tr> <tr> <td>Result:</td> <td>Inhibited ASG cells proliferation with IC₅₀s of 28.7, 14.6 and 8.1 μM, respectively, for 30 μM, 60 μM, and 90 μM treatment.</td> </tr> </table>	Cell Line:	Cimicide E. AGS cells	Concentration:	30 μM, 60 μM, and 90 μM	Incubation Time:	3 h, 6 h, 12 h, and 24 h	Result:	Increased the ratio of Bax/Bcl-2 expression from 60 μM. Decreased mutant type (mt) p53 level from 12 h at 30 μM. Suppressed the protein level of procaspase 3 in a dose-dependent manner from 30 μM.	Cell Line:	Cimicide E. AGS cells	Concentration:	30 μM, 60 μM, and 90 μM	Incubation Time:	12 h, 24 h, and 48 h	Result:	Inhibited ASG cells proliferation with IC ₅₀ s of 28.7, 14.6 and 8.1 μM, respectively, for 30 μM, 60 μM, and 90 μM treatment.
Cell Line:	Cimicide E. AGS cells																
Concentration:	30 μM, 60 μM, and 90 μM																
Incubation Time:	3 h, 6 h, 12 h, and 24 h																
Result:	Increased the ratio of Bax/Bcl-2 expression from 60 μM. Decreased mutant type (mt) p53 level from 12 h at 30 μM. Suppressed the protein level of procaspase 3 in a dose-dependent manner from 30 μM.																
Cell Line:	Cimicide E. AGS cells																
Concentration:	30 μM, 60 μM, and 90 μM																
Incubation Time:	12 h, 24 h, and 48 h																
Result:	Inhibited ASG cells proliferation with IC ₅₀ s of 28.7, 14.6 and 8.1 μM, respectively, for 30 μM, 60 μM, and 90 μM treatment.																

Cell Cycle Analysis^[1]

Cell Line:	Cimiside E. AGS cells
Concentration:	30 μ M, 60 μ M, and 90 μ M
Incubation Time:	3 h, 6 h, and 24 h
Result:	Induced cell cycle arrest at S phase in a low concentration (30 μ M), but arrested cell cycle at G2/M phase in higher concentration (60 μ M and 90 μ M).

REFERENCES

[1]. Guo LY, et al. Cimiside E arrests cell cycle and induces cell apoptosis in gastric cancer cells. Arch Pharm Res. 2009 Oct;32(10):1385-92.

[2]. Jamróz MK, et al. One new and six known triterpene xylosides from Cimicifuga racemosa: FT-IR, Raman and NMR studies and DFT calculations. Spectrochim Acta A Mol Biomol Spectrosc. 2012 Jul;93:10-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA